For example, CAR T therapy specific for glioma antigen resulted in pro-inflammatory cytokine secretion and an altered immune-cell landscape, with an increase in CD8+ T cells and a decrease in MDSCs in tumor-bearing mice grafted with a human glioma cell line [150]. This evidence concerns the gene CD8A and central nervous system cancer.